Status:
COMPLETED
Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Lymphoid Neoplasm
Eligibility:
All Genders
Brief Summary
Although modern radiation techniques combined with chemotherapy has greatly improved the local control and long-term survivals for patients with early-stage NKTCL, relapse and systemic dissemination a...
Eligibility Criteria
Inclusion
- Diagnosis of NKTCL with typical morphology and immunophenotype, according to the 2008 World Health Organization classification of lymphomas;
- stage III/IV disease; or relapsed or refractory disease after at least one line prior teratment;
- age ≥ 18 years;
- ECOG performance status 0-2;
- at least one measurable lesion;
- adequate hematological, hepatic, and renal functions;
- life expectancy of more than 3 months.
Exclusion
- Previously untreated stage I/II disease;
- with no adequate tumour tissue;
- any coexisting medical problems of sufficient severity to prevent full compliance with the study protocol.
Key Trial Info
Start Date :
May 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04509804
Start Date
May 10 2018
End Date
January 1 2020
Last Update
August 12 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mei Dong
Beijing, Beijing Municipality, China, 100021